FREMONT, Calif., April 18, 2017 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a late-stage clinical company focused on enhancing
the treatment of patients with cardiorenal and gastrointestinal
(GI) diseases, today announced that it will present clinical and
preclinical data during two poster presentations at the following
upcoming medical meetings:
National Kidney Foundation Spring Clinical Meetings,
April 18 – 22, 2017, in Orlando, Fla.
Date and Time: Wednesday, April 19,
2017 from 6:00 – 7:30p.m.
ET
Poster Title: Effect of Tenapanor on Serum Fibroblast Growth
Factor 23 Levels
Poster Number: 193
Digestive Disease Week, May 6 – 9,
2017, in Chicago
Date and Time: Tuesday, May 9,
2017 from 12:00 – 2:00p.m.
CT
Session Title: Clinical Steatohepatitis
Poster Title: Minimally-systemic TGR5 agonist RDX8940
improves hepatic steatosis and insulin sensitivity in
Western-diet-fed mice
Poster Number: Tu1559
About Ardelyx, Inc.
Ardelyx is focused on enhancing
the way patients with cardiorenal and gastrointestinal (GI)
diseases are treated by using the gut as the gateway to delivering
medicines that matter. The company has established unique
cardiorenal and GI business units aimed at bringing new, effective
medicines with distinct safety and dosing advantages to underserved
patients. Ardelyx's cardiorenal portfolio includes the Phase 3
development of tenapanor for the treatment of hyperphosphatemia in
people with end-stage renal disease who are on dialysis and the
Phase 3 development of RDX7675 for the treatment of people with
hyperkalemia. The company's GI portfolio includes the Phase 3
development of tenapanor for the treatment of people with irritable
bowel syndrome with constipation (IBS-C), and RDX8940, a TGR5
agonist approaching Phase 1 development. Leveraging the company's
platform and unique gut-restriction chemistry, Ardelyx intends to
build a fully integrated, revenue-generating biopharmaceutical
company with leading cardiorenal and GI business units. For more
information, please visit www.ardelyx.com and connect with us on
Twitter @Ardelyx.
Forward Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding Ardelyx, they are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor of the Private
Securities Reform Act of 1995, including the potential for
Ardelyx's product candidates in treating the diseases and
conditions for which they are being developed and Ardelyx's
corporate plans and goals. Such forward-looking statements involve
substantial risks and uncertainties that could cause the
development of Ardelyx's product candidates or Ardelyx's future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in research and the clinical development. Ardelyx
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Ardelyx's business in general, please refer to
Ardelyx's Quarterly Report on Form 10-K filed with the Securities
and Exchange Commission on February 17,
2017, and its future current and periodic reports to be
filed with the Securities and Exchange Commission.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-upcoming-spring-medical-meetings-300440554.html
SOURCE Ardelyx